Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post–EMA-approval descriptive study with a geriatric oncology focus
This was a post–European medicine agency marketing (EMA-M) study
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Background/Aims: The Bretagne-Pays de la Loire cancer observatory, an oncology network created by the French Ministry of Health, is specifically dedicated to assess the use of new targeted anticancer therapies in routine practice.
📊
Temel Bulgular & Veri:In line with the French National Cancer III program, our cancer network set up a real-life cohort, which is independent of the pharmaceutical industry, for patients with colorectal cancer to monitor patient safety and quality of care and promote pharmacovigilance.Materials and Methods: Panitumumab monotherapy was assessed in 243 patients with wild-type Kirsten rat sarcoma who were treated for metastatic colorectal cancer (mCRC) between July 2008 and December 2010 after prior chemotherapy using oxaliplatine and irinotec-an.
💡
Sonuç & Katkı:This was a post–European medicine agency marketing (EMA-M) study
🔬Tür:Araştırma Makalesi
📍Kapsam:2008 Verileri
⚙️Değişkenler:Alan Parametreleri
Özet
Background/Aims: The Bretagne-Pays de la Loire cancer observatory, an oncology network created by the French Ministry of Health, is specifically dedicated to assess the use of new targeted anticancer therapies in routine practice. In line with the French National Cancer III program, our cancer network set up a real-life cohort, which is independent of the pharmaceutical industry, for patients with colorectal cancer to monitor patient safety and quality of care and promote pharmacovigilance.Materials and Methods: Panitumumab monotherapy was assessed in 243 patients with wild-type Kirsten rat sarcoma who were treated for metastatic colorectal cancer (mCRC) between July 2008 and December 2010 after prior chemotherapy using oxaliplatine and irinotec-an. This was a post–European medicine agency marketing (EMA-M) study
🔖
Bu Makaleye Atıf Yap
METGES, J. P., DOULLLARD, J., RAMEE, J., DUPUIS, O., SENELLART, H., PORNEUF, M., DEGUIRAL, P., ACHOUR, N. E., CUMIN, I., EDELINE, J., ARTIGNAN, X., FAROUX, R., STAMPFLİ, C., COJOCARASU, O., GOURLAOUEN, A., BIDEAU, K., MEYER, V. R. G. R., FIC, A. (2020). Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post–EMA-approval descriptive study with a geriatric oncology focus. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 10, 695–705. https://ajindex.com/articles/410015
Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxal-iplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010
[Crossref] 2. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOL-FIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010
[Crossref] 3. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leu-covorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009
[Crossref] 4. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008
[Crossref] 5. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008
[Crossref] 6. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007
[Crossref] 7. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best sup-portive care alone in patients with chemotherapy-refractory meta-static colorectal cancer. J Clin Oncol 2007
[Crossref] 8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monothera-py and cetuximab plus irinotecan in irinotecan-refractory metastat-ic colorectal cancer. N Engl J Med 2004
[Crossref] 9. Mendelsohn J, Baselga J. Epidermal growth factor receptor target-ing in cancer. Semin Oncol 2006
[Crossref] 10. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005
[Crossref] 11. Metges JP, Gamelin E, Grudé F, et al. European reglementation for cetuximab still required the EGFR positive status: Results of a French Translational Study OMIT of 329 patients to define if this criteria is relevant. 2010
35th ESMO congress A4395. 12. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colo